OligoNova Phase 1
| Reference number | |
| Coordinator | Göteborgs universitet - Institutionen för biomedicin |
| Funding from Vinnova | SEK 1 717 412 |
| Project duration | June 2020 - November 2022 |
| Status | Completed |
| Venture | SWElife, strategic project |
Important results from the project
Our intention with this project was to implement a national effort in the field of therapeutic oligonucleotides - OligoNova. Through close collaboration, joint activities and new investments from academia, healthcare and industry, we have now developed a Swedish platform for world-class therapeutic oligonucleotides, with global visibility and impact. We have initiated work to develop ground-breaking therapies that lead to patient benefit and strengthen Sweden´s competitiveness within Life Science.
Expected long term effects
We have established a national platform, a hub for research and innovation within therapeutic oligonucleotides in Sweden. Industrial and academic research environments, as well as actors in health and healthcare have been linked to the platform and a physical center has been established in Gothenburg. We have created the conditions to go from current outstanding research to developing ground-breaking therapies that can be implemented in healthcare in the future.
Approach and implementation
We have carried out a national mobilization of relevant actors. This has laid the foundation for joint research and innovation processes. We have established a physical center for the development of therapeutic oligonucleotides and opened up collaboration with national actors. We are in the process of developing a programme for further commercialization and rapid implementation of the new therapies developed within the OligoNova project.